Abbott Laboratories
Thesis
Abbott is a diversified healthcare company with significant revenue from its pharmaceutical products, including Humira, which is currently facing market concerns. Despite this, Abbott has leading businesses in stents, nutrition, and cardiovascular, indicating strong underlying value.
Did it work?
inconclusive
confidence: low
No price performance data or elapsed time is available, so the return-based leg of the thesis cannot be evaluated. The thesis is a general diversification/underlying-value argument without a specific, checkable catalyst, and it contains an ambiguity — Humira was Abbott's drug only until the 2013 AbbVie spinoff — making it unclear which era of Abbott this refers to. With nothing decisively confirmed or invalidated, the verdict is inconclusive.